Press + Media Contact
Cylance PR Team
IRVINE, CALIFORNIA, May 16, 2018 - Cylance® Inc., the company that revolutionised endpoint security with true AI powered threat prevention, today announced that VolitionRx Limited, a cancer diagnostic company, has implemented CylancePROTECT to prevent malicious activity targeting endpoint devices before it can endanger sensitive patient information.
VolitionRx Limited is a multi-national life sciences company focused on developing new ways to detect cancer. Current cancer diagnosis often involves expensive, unpleasant, and/or invasive testing. Volition’s goal is to diagnose a range of cancers quickly, accurately, and inexpensively, thereby reducing strain on over-burdened healthcare systems. With critical information stored across their systems and with the healthcare industry being one of the most targeted for cyber-attacks, security for Volition RX is paramount.
"At VolitionRx, it had become quite clear that we needed a new endpoint security solution that provided us with worldwide coverage and visibility of all the devices in real time," said Daniel Halter, Group IT Manager at VolitionRx. "We were able to test Cylance against other well-known anti-virus solutions and found Cylance was always protecting and identifying threats which we hadn’t previously seen - it really did just work. Having CylancePROTECT and its advanced, predictive algorithm in place, ensures we are safe and secured."
Handling the process was KHIPU Networks, which VolitionRx consulted for security solution recommendations. Having ran multiple tests, KHIPU was able to showcase CylancePROTECT’s threat detection capabilities and ease of use and seamless integration with other security software. The solution’s low consumption on endpoint devices was an additional benefit, especially for older hardware devices in operation.
Matt Ashman, CCO and Co-founder at KHIPU Networks commented on the reasoning behind the choice of CylancePROTECT saying, "The key reason KHIPU chose Cylance was not only does the platform detect and prevent vulnerabilities, it also predicts and eliminates them. This is extremely important in any environment – having that level of control, visibility and automation, can protect your environments against ever-changing cyber-attacks."
CylancePROTECT is an integrated threat prevention solution that combines the power of artificial intelligence (AI) to block malware infections with additional security controls that safeguard against script-based, fileless, memory, and external device based attacks.
Whether fighting cancer or malware, VolitionRx and Cylance both share a common, proactive approach to keeping people safe. With CylancePROTECT, Volition’s security posture will be enhanced with devices being protected in real time, especially against the ever-growing risk of ransomware and zero-day attacks.
Read the full case study for more technical details.
In addition, you can watch the VolitionRx video testimonial here.
About Cylance® Inc.
Cylance is the first company to apply artificial intelligence, algorithmic science, and machine learning to cybersecurity to prevent the most advanced security threats in the world. Built on a breakthrough predictive analysis process, the Cylance AI Platform serves as a foundation for innovative, AI driven security products to address critical attack vectors. The company’s flagship product, CylancePROTECT, quickly and accurately identifies what is benign and what is a threat, and prevents malicious code from ever executing on a targeted system. By coupling advanced machine learning and artificial intelligence with a unique understanding of an attacker’s mentality, Cylance provides technology and services that are truly predictive and preventive against the most advanced threats. For more information visit: www.cylance.com
Cylance and CylancePROTECT are registered trademarks or trademarks owned by Cylance Inc. in the United States and other jurisdictions and may not be used without prior written permission. All other trademarks are the property of their respective owners.